Lv1
42 积分 2024-09-14 加入
AML treatment: conventional chemotherapy and emerging novel agents
1天前
待确认
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies
3天前
已完结
Mechanism of Initial Favorable Response to Decitabine in TP53 -Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse
4天前
已完结
Engineering CAR-T therapies for autoimmune disease and beyond.
1个月前
已完结
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
1个月前
已完结
Single-cell profiling of immune system alterations in lymphoid, barrier and solid tissues in aged mice
1个月前
已完结
Advancements and challenges in CAR T cell therapy in autoimmune diseases
2个月前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
2个月前
已完结
Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia
2个月前
已完结
Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging
2个月前
已关闭
皖公网安备34019202002308
